On January 28, 2021 OSE Immunotherapeutics reported a new collaboration agreement with MAbSilico, a deep technology innovative TechBio located in Tours, France, to use artificial intelligence (AI)-based software for therapeutic monoclonal antibody drug development (Press release, OSE Immunotherapeutics, JAN 28, 2021, View Source [SID1234646990]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Nicolas Poirier, Chief Scientific Officer of OSE Immunotherapeutics, stated: "Expansion of our collaboration with MAbSilico to ten additional programs reflects our shared conviction that we can meaningfully improve and accelerate drug discovery, by pairing the knowledge and expertise of our R&D teams with the innovative technologies offered by MAbSilico. This perfectly complements the Company’s evolving business strategy to build a competitive development engine and bring more products into the clinic, hence accelerating and expanding our clinical stage portfolio in immunotherapy."
OSE Immunotherapeutics and MAbSilico entered into an initial agreement early 2020 to apply innovative AI-based solutions to six programs aiming at accelerating the characterization and optimization of monoclonal antibodies and therapeutic proteins for OSE to investigate as therapeutic agents.
Through this expanded agreement, both companies reinforce and extend the scope of the collaboration to use MAbSilico software for ten additional development programs of antibody drugs in immuno-oncology, inflammation and autoimmune diseases for OSE.
Furthermore, both companies are bringing together their unparalleled expertise in the field of AI and antibody-based therapies to develop a disruptive computational in silico Antibody Discovery and Design platform combining OSE’s database and expertise with MAbSilico’s AI-tools.
MAbSilico software, including AI, numerical simulation and data mining, is being used to guide therapeutic antibody discovery, help reduce the risk of failure and accelerate the preclinical development process of antibody drug candidates, with the objectives of speeding up the start of clinical testing.
This new collaboration between OSE Immunotherapeutics and MAbSilico aims to:
Accelerate the development of OSE’s "Immunotherapy 2.0" drug candidates by using AI, including machine learning and algorithms, at a very early stage in the process of monoclonal antibody discovery and optimization (AI-driven drug discovery); – Demonstrate how in silico software for computational antibody discovery and design can disrupt traditional drug development processes and timelines, from the selection of a promising epitope to the optimization of the final humanized lead. The very complementary knowledge of OSE’s antibody expertise, knowledge and databases with MAbSilico’s AI expertise and antibodydedicated deep tech technologies gathered in its integrated software, MAbFactory, is a revolution for antibody development.